Login Register Cart 0
Generic placeholder image

Current Pharmaceutical Design

Editor-in-Chief

ISSN (Print): 1381-6128
ISSN (Online): 1873-4286

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Review Article

Controversies in the Pharmacotherapy of Adolescent Depression

Author(s): Gabriele Masi*

Volume 28, Issue 24, 2022

Published on: 18 July, 2022

Page: [1975 - 1984] Pages: 10

DOI: 10.2174/1381612828666220526150153

Price: $65

Abstract

Background: Although fluoxetine and, in the USA, escitalopram are approved for depression in adolescence, substantial concern surrounds antidepressant use in youth. Major controversies regarding the efficacy and safety (increased suicidality) of antidepressants exist.

Introduction: The category of depression is very broad and overinclusive in terms of etiology, the role of psychosocial adversities severity, episodicity, presentation, and relationship with bipolarity. This heterogeneity, not fully considered in Randomized Controlled Trials (RCTs), may account for the disappointing results with respect to both the efficacy and safety.

Methods: Based on the available literature, we will address the following topics: a) controversies regarding the definition of depression as a unique homogeneous condition with a unique type of pharmacological treatment; b) controversies about the interpretation of data from Randomized Controlled Trials (RCTs) on the efficacy of pharmacological treatments in adolescent depression; c) the interpretation of data regarding the safety of antidepressant treatment in adolescent depression, particularly in terms of increased suicidal risk.

Results: According to RCTs, antidepressants are minimally to moderately more effective than placebo, principally based on very high placebo responses, and only fluoxetine shows more evidence of efficacy. These differences in meta-analyses are sometimes statistically but not clinically significant. Depression is a heterogeneous condition in terms of etiology, the role of psychosocial adversities severity, episodicity, presentation, and relationship with bipolarity. This heterogeneity may partly explain the low drug-placebo difference and the high placebo response (possibly related to a high level of natural recovery of adolescent depression). In the National Institute of Mental Health (NIMH)-funded studies, including a lower number of study sites and more reliable enrollment procedures, lower placebo response rates and greater group differences between medication and placebo were found. Robust evidence supports an increased risk of emergent suicidality after starting antidepressants. A clear age effect on suicidal risk after antidepressants is supported by a comprehensive meta-analysis, showing that suicidal risk increases with decreasing age, being markedly greater in subjects aged between 18 and 25 years. However, the term suicidality is too broad, as it includes suicidal ideation, suicidal attempts, and completed suicide, with a wide range of severity and pervasiveness. If emergent suicidality should be actively and carefully explored, empirical evidence, albeit weak, suggests that combined pharmacotherapy (antidepressant and/or lithium) associated with psychotherapy may be helpful in reducing pretreatment suicidal ideation and suicidal risk.

Conclusion: Moderate to severe depression should be treated with psychotherapy and/or fluoxetine, the bestsupported medication, and treatment-resistant adolescents should always receive combined treatment with psychotherapy. Suicidal ideation, particularly with a plan, should be actively explored before starting an antidepressant, as a reason for the closest monitoring. Emergent suicidality after starting antidepressants, as well as antidepressant-related activation, should also be closely monitored and may lead to antidepressant discontinuation. Although no response to pharmacotherapy and psychotherapy may occur in up to 40% of depressed adolescents, possible predictors or mediators of poorer response in adolescents are uncertain, and only a few studies support possible treatment strategies. Finally, studies exploring the efficacy of antidepressants in specific depression subtypes, i.e., based on prevalent psychopathological dimensions (apathy, withdrawal, impulsivity), are warranted.

Keywords: Depression, adolescence, pharmacotherapy, suicidality, major depressive disorder, psychopathological dimensions.

« Previous Next »
[1]
Olfson M, Marcus SC, Druss BG. Effects of food and drug administration warnings on antidepressant use in a national sample. Arch Gen Psychiatry 2008; 65(1): 94-101.
[http://dx.doi.org/10.1001/archgenpsychiatry.2007.5] [PMID: 18180433]
[2]
Bachmann CJ, Aagaard L, Burcu M, et al. Trends and patterns of antidepressant use in children and adolescents from five western countries, 2005-2012. Eur Neuropsychopharmacol 2016; 26(3): 411-9.
[http://dx.doi.org/10.1016/j.euroneuro.2016.02.001] [PMID: 26970020]
[3]
Ghaemi SN. Why antidepressants are not antidepressants: STEP-BD, STAR*D, and the return of neurotic depression. Bipolar Disord 2008; 10(8): 957-68.
[http://dx.doi.org/10.1111/j.1399-5618.2008.00639.x] [PMID: 19594510]
[4]
Stringaris A. Editorial: What is depression? J Child Psychol Psychiatry 2017; 58(12): 1287-9.
[http://dx.doi.org/10.1111/jcpp.12844] [PMID: 29148049]
[5]
Lynch CJ, Gunning FM, Liston C. Causes and consequences of diagnostic heterogeneity in depression: Paths to discovering novel biological depression subtypes. Biol Psychiatry 2020; 88(1): 83-94.
[http://dx.doi.org/10.1016/j.biopsych.2020.01.012] [PMID: 32171465]
[6]
Regier DA, Narrow WE, Clarke DE, et al. DSM-5 field trials in the United States and Canada, Part II: test-retest reliability of selected categorical diagnoses. Am J Psychiatry 2013; 170(1): 59-70.
[http://dx.doi.org/10.1176/appi.ajp.2012.12070999] [PMID: 23111466]
[7]
Cipriani A, Zhou X, Del Giovane C, et al. Comparative efficacy and tolerability of antidepressants for major depressive disorder in children and adolescents: a network meta-analysis. Lancet 2016; 388(10047): 881-90.
[http://dx.doi.org/10.1016/S0140-6736(16)30385-3] [PMID: 27289172]
[8]
Walkup JT. Antidepressant efficacy for depression in children and adolescents: Industry- and NIMH-funded studies. Am J Psychiatry 2017; 174(5): 430-7.
[http://dx.doi.org/10.1176/appi.ajp.2017.16091059] [PMID: 28253735]
[9]
March J, Silva S, Petrycki S, et al. Fluoxetine, cognitive-behavioral therapy, and their combination for adolescents with depression: Treatment for adolescents with depression study (TADS) randomized controlled trial. JAMA 2004; 292(7): 807-20.
[http://dx.doi.org/10.1001/jama.292.7.807] [PMID: 15315995]
[10]
Kirsch I, Deacon BJ, Huedo-Medina TB, Scoboria A, Moore TJ, Johnson BT. Initial severity and antidepressant benefits: a meta-analysis of data submitted to the Food and Drug Administration. PLoS Med 2008; 5(2)e45
[http://dx.doi.org/10.1371/journal.pmed.0050045] [PMID: 18303940]
[11]
Fournier JC, DeRubeis RJ, Hollon SD, et al. Antidepressant drug effects and depression severity: a patient-level meta-analysis. JAMA 2010; 303(1): 47-53.
[http://dx.doi.org/10.1001/jama.2009.1943] [PMID: 20051569]
[12]
Curry J, Rohde P, Simons A, et al. Predictors and moderators of acute outcome in the treatment for adolescents with depression study (TADS). J Am Acad Child Adolesc Psychiatry 2006; 45(12): 1427-39.
[http://dx.doi.org/10.1097/01.chi.0000240838.78984.e2] [PMID: 17135988]
[13]
Rabinowitz J, Werbeloff N, Mandel FS, Menard F, Marangell L, Kapur S. Initial depression severity and response to antidepressants v. placebo: patient-level data analysis from 34 randomised controlled trials. Br J Psychiatry 2016; 209(5): 427-8.
[http://dx.doi.org/10.1192/bjp.bp.115.173906] [PMID: 27198482]
[14]
Furukawa TA, Maruo K, Noma H, et al. Initial severity of major depression and efficacy of new generation antidepressants: individual participant data meta-analysis. Acta Psychiatr Scand 2018; 137(6): 450-8.
[http://dx.doi.org/10.1111/acps.12886] [PMID: 29611870]
[15]
Hieronymus F, Lisinski A, Nilsson S, Eriksson E. Influence of baseline severity on the effects of SSRIs in depression: an item-based, patient-level post-hoc analysis. Lancet Psychiatry 2019; 6(9): 745-52.
[http://dx.doi.org/10.1016/S2215-0366(19)30216-0] [PMID: 31303567]
[16]
Maslej MM, Furukawa TA, Cipriani A, et al. Individual differences in response to antidepressants: A meta-analysis of placebo-controlled randomized clinical trials. JAMA Psychiatry 2021; 78(5): 490-7.
[http://dx.doi.org/10.1001/jamapsychiatry.2020.4564] [PMID: 33595620]
[17]
Strawn JR, Aaronson ST, Elmaadawi AZ, et al. Treatment-resistant depression in adolescents: Clinical features and measurement of treatment resistance. J Child Adolesc Psychopharmacol 2020; 30(4): 261-6.
[http://dx.doi.org/10.1089/cap.2020.0008] [PMID: 32315537]
[18]
Lorenzo-Luaces L, Rodriguez-Quintana N, Bailey AJ. Double trouble: Do symptom severity and duration interact to predicting treatment outcomes in adolescent depression? Behav Res Ther 2020; 131103637
[http://dx.doi.org/10.1016/j.brat.2020.103637] [PMID: 32413595]
[19]
McMakin DL, Olino TM, Porta G, et al. Anhedonia predicts poorer recovery among youth with selective serotonin reuptake inhibitor treatment-resistant depression. J Am Acad Child Adolesc Psychiatry 2012; 51(4): 404-11.
[http://dx.doi.org/10.1016/j.jaac.2012.01.011] [PMID: 22449646]
[20]
Nanni V, Uher R, Danese A. Childhood maltreatment predicts unfavorable course of illness and treatment outcome in depression: a meta-analysis. Am J Psychiatry 2012; 169(2): 141-51.
[http://dx.doi.org/10.1176/appi.ajp.2011.11020335] [PMID: 22420036]
[21]
Shamseddeen W, Asarnow JR, Clarke G, et al. Impact of physical and sexual abuse on treatment response in the treatment of resistant depression in adolescent study (TORDIA). J Am Acad Child Adolesc Psychiatry 2011; 50(3): 293-301.
[http://dx.doi.org/10.1016/j.jaac.2010.11.019] [PMID: 21334569]
[22]
Benazzi F. Bipolar disorder--focus on bipolar II disorder and mixed depression. Lancet 2007; 369(9565): 935-45.
[http://dx.doi.org/10.1016/S0140-6736(07)60453-X] [PMID: 17368155]
[23]
Frazier EA, Swenson LP, Mullare T, Dickstein DP, Hunt JI. Depression with mixed features in adolescent psychiatric patients. Child Psychiatry Hum Dev 2017; 48(3): 393-9.
[http://dx.doi.org/10.1007/s10578-016-0666-z] [PMID: 27349656]
[24]
Goldberg JF, Perlis RH, Ghaemi SN, et al. Adjunctive antidepressant use and symptomatic recovery among bipolar depressed patients with concomitant manic symptoms: findings from the STEP-BD. Am J Psychiatry 2007; 164(9): 1348-55.
[http://dx.doi.org/10.1176/appi.ajp.2007.05122032] [PMID: 17728419]
[25]
Maalouf FT, Porta G, Vitiello B, et al. Do sub-syndromal manic symptoms influence outcome in treatment resistant depression in adolescents? A latent class analysis from the TORDIA study. J Affect Disord 2012; 138(1-2): 86-95.
[http://dx.doi.org/10.1016/j.jad.2011.12.021] [PMID: 22284022]
[26]
O’Donovan C, Alda M. Depression preceding diagnosis of bipolar disorder. Front Psychiatry 2020; 11: 500.
[http://dx.doi.org/10.3389/fpsyt.2020.00500] [PMID: 32595530]
[27]
Schuler MS, Gilman SE, Burns RM, Roth E, Breslau J. Associations between depression subtype and functional impairment and treatment utilization in a national sample of adolescents. J Affect Disord 2021; 287: 26-33.
[http://dx.doi.org/10.1016/j.jad.2021.03.018] [PMID: 33765539]
[28]
Goldberg DP, Wittchen H-U, Zimmermann P, Pfister H, Beesdo-Baum K. Anxious and non-anxious forms of major depression: familial, personality and symptom characteristics. Psychol Med 2014; 44(6): 1223-34.
[http://dx.doi.org/10.1017/S0033291713001827] [PMID: 23902895]
[29]
Häberling I, Baumgartner N, Emery S, et al. Anxious depression as a clinically relevant subtype of pediatric major depressive disorder. J Neural Transm (Vienna) 2019; 126(9): 1217-30.
[http://dx.doi.org/10.1007/s00702-019-02069-x] [PMID: 31456039]
[30]
Cosgrove KT, Burrows K, Avery JA, et al. Appetite change profiles in depression exhibit differential relationships between systemic inflammation and activity in reward and interoceptive neurocircuitry. Brain Behav Immun 2020; 83: 163-71.
[http://dx.doi.org/10.1016/j.bbi.2019.10.006] [PMID: 31604141]
[31]
Toenders YJ, Schmaal L, Harrison BJ, Dinga R, Berk M, Davey CG. Neurovegetative symptom subtypes in young people with major depressive disorder and their structural brain correlates. Transl Psychiatry 2020; 10(1): 108.
[http://dx.doi.org/10.1038/s41398-020-0787-9] [PMID: 32312958]
[32]
Baller EB, Kaczkurkin AN, Sotiras A, et al. Neurocognitive and functional heterogeneity in depressed youth. Neuropsychopharmacology 2021; 46(4): 783-90.
[http://dx.doi.org/10.1038/s41386-020-00871-w] [PMID: 33007777]
[33]
Tisseyre L, Lacourse E, Labelle R, et al. A person-centered approach to studying associations between psychosocial vulnerability factors and adolescent depressive symptoms and suicidal ideation in a Canadian longitudinal sample Dev Psychopathol 2021; 33(1): 351-62.
[http://dx.doi.org/10.1017/S0954579420000012] [PMID: 32381149]
[34]
D’Acunto G, Nageye F, Zhang J, Masi G, Cortese S. Inflammatory cytokines in children and adolescents with depressive disorders: A systematic review and meta-analysis. J Child Adolesc Psychopharmacol 2019; 29(5): 362-9.
[http://dx.doi.org/10.1089/cap.2019.0015] [PMID: 30939048]
[35]
Wang L, Wang R, Liu L, Qiao D, Baldwin DS, Hou R. Effects of SSRIs on peripheral inflammatory markers in patients with major depressive disorder: A systematic review and meta-analysis. Brain Behav Immun 2019; 79: 24-38.
[http://dx.doi.org/10.1016/j.bbi.2019.02.021] [PMID: 30797959]
[36]
Dwyer JB, Bloch MH. Antidepressants for Pediatric Patients. Curr Psychiatr 2019; 18(9): 26-42F.
[PMID: 31511767]
[37]
Zhou X, Teng T, Zhang Y, et al. Comparative efficacy and acceptability of antidepressants, psychotherapies, and their combination for acute treatment of children and adolescents with depressive disorder: a systematic review and network meta-analysis. Lancet Psychiatry 2020; 7(7): 581-601.
[http://dx.doi.org/10.1016/S2215-0366(20)30137-1] [PMID: 32563306]
[38]
Hetrick SE, McKenzie JE, Bailey AP, et al. New generation antidepressants for depression in children and adolescents: a network meta-analysis. Cochrane Database Syst Rev 2021; 5(5)CD013674
[PMID: 34029378]
[39]
Bridge JA, Iyengar S, Salary CB, et al. Clinical response and risk for reported suicidal ideation and suicide attempts in pediatric antidepressant treatment: a meta-analysis of randomized controlled trials. JAMA 2007; 297(15): 1683-96.
[http://dx.doi.org/10.1001/jama.297.15.1683] [PMID: 17440145]
[40]
Boaden K, Tomlinson A, Cortese S, Cipriani A. Antidepressants in children and adolescents: Meta-review of efficacy, tolerability and suicidality in acute treatment. Front Psychiatry 2020; 11: 717.
[http://dx.doi.org/10.3389/fpsyt.2020.00717] [PMID: 32982805]
[41]
Cipriani A, Furukawa TA, Salanti G, et al. Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis. Lancet 2018; 391(10128): 1357-66.
[http://dx.doi.org/10.1016/S0140-6736(17)32802-7] [PMID: 29477251]
[42]
Li Y, Huang J, He Y, et al. The impact of placebo response rates on clinical trial outcome: A systematic review and meta-analysis of antidepressants in children and adolescents with major depressive disorder. J Child Adolesc Psychopharmacol 2019; 29(9): 712-20.
[http://dx.doi.org/10.1089/cap.2019.0022] [PMID: 31368787]
[43]
DelBello MP, Chang K, Welge JA, et al. A double-blind, placebo-controlled pilot study of quetiapine for depressed adolescents with bipolar disorder. Bipolar Disord 2009; 11(5): 483-93.
[http://dx.doi.org/10.1111/j.1399-5618.2009.00728.x] [PMID: 19624387]
[44]
Brent D, Emslie G, Clarke G, et al. Switching to another SSRI or to venlafaxine with or without cognitive behavioral therapy for adolescents with SSRI-resistant depression: the TORDIA randomized controlled trial. JAMA 2008; 299(8): 901-13.
[http://dx.doi.org/10.1001/jama.299.8.901] [PMID: 18314433]
[45]
Bridge JA, Birmaher B, Iyengar S, Barbe RP, Brent DA. Placebo response in randomized controlled trials of antidepressants for pediatric major depressive disorder. Am J Psychiatry 2009; 166(1): 42-9.
[http://dx.doi.org/10.1176/appi.ajp.2008.08020247] [PMID: 19047322]
[46]
Wagner KD, Jonas J, Findling RL, Ventura D, Saikali K. A double-blind, randomized, placebo-controlled trial of escitalopram in the treatment of pediatric depression. J Am Acad Child Adolesc Psychiatry 2006; 45(3): 280-8.
[http://dx.doi.org/10.1097/01.chi.0000192250.38400.9e] [PMID: 16540812]
[47]
Emslie GJ, Findling RL, Yeung PP, Kunz NR, Li Y. Venlafaxine ER for the treatment of pediatric subjects with depression: results of two placebo-controlled trials. J Am Acad Child Adolesc Psychiatry 2007; 46(4): 479-88.
[http://dx.doi.org/10.1097/chi.0b013e31802f5f03] [PMID: 17420682]
[48]
Meister R, Abbas M, Antel J, et al. Placebo response rates and potential modifiers in double-blind randomized controlled trials of second and newer generation antidepressants for major depressive disorder in children and adolescents: a systematic review and meta-regression analysis. Eur Child Adolesc Psychiatry 2020; 29(3): 253-73.
[http://dx.doi.org/10.1007/s00787-018-1244-7] [PMID: 30535589]
[49]
Goodyer IM, Wilkinson PO. Practitioner Review: Therapeutics of unipolar major depressions in adolescents. J Child Psychol Psychiatry 2019; 60(3): 232-43.
[http://dx.doi.org/10.1111/jcpp.12940] [PMID: 29939396]
[50]
Eap CB, Gründer G, Baumann P, et al. Tools for optimising pharmacotherapy in psychiatry (therapeutic drug monitoring, molecular brain imaging and pharmacogenetic tests): focus on antidepressants. World J Biol Psychiatry 2021; 22(8): 561-628.
[http://dx.doi.org/10.1080/15622975.2021.1878427] [PMID: 33977870]
[51]
Fekete S, Hiemke C, Gerlach M. Dose-related concentrations of neuroactive/psychoactive drugs expected in blood of children and adolescents. Ther Drug Monit 2020; 42(2): 315-24.
[http://dx.doi.org/10.1097/FTD.0000000000000685] [PMID: 32195989]
[52]
Fekete S, Scherf-Clavel M, Gerlach M, et al. Dose-corrected serum concentrations and metabolite to parent compound ratios of venlafaxine and risperidone from childhood to old age. Pharmacopsychiatry 2021; 54(3): 117-25.
[http://dx.doi.org/10.1055/a-1302-8108] [PMID: 33291155]
[53]
Emslie GJ, Kennard BD, Mayes TL, et al. Continued effectiveness of relapse prevention cognitive-behavioral therapy following fluoxetine treatment in youth with major depressive disorder. J Am Acad Child Adolesc Psychiatry 2015; 54(12): 991-8.
[http://dx.doi.org/10.1016/j.jaac.2015.09.014] [PMID: 26598474]
[54]
Asarnow JR, Porta G, Spirito A, et al. Suicide attempts and nonsuicidal self-injury in the treatment of resistant depression in adolescents: findings from the TORDIA study. J Am Acad Child Adolesc Psychiatry 2011; 50(8): 772-81.
[http://dx.doi.org/10.1016/j.jaac.2011.04.003] [PMID: 21784297]
[55]
Goodyer I, Dubicka B, Wilkinson P, et al. Selective serotonin reuptake inhibitors (SSRIs) and routine specialist care with and without cognitive behaviour therapy in adolescents with major depression: Randomised controlled trial. BMJ 2007; 335(7611): 142.
[http://dx.doi.org/10.1136/bmj.39224.494340.55] [PMID: 17556431]
[56]
Whittington GJ, Kendall T, Fonagy P, et al. Selective serotonin reuptake inhibitors in childhood depression: systematic review of published versus unpublished data Lancet 2004; 363: 1341-5.
[http://dx.doi.org/10.1016/S0140-6736(04)16043-1]
[57]
Hammad TA, Laughren T, Racoosin J. Suicidality in pediatric patients treated with antidepressant drugs. Arch Gen Psychiatry 2006; 63(3): 332-9.
[http://dx.doi.org/10.1001/archpsyc.63.3.332] [PMID: 16520440]
[58]
Stone M, Laughren T, Jones ML, et al. Risk of suicidality in clinical trials of antidepressants in adults: analysis of proprietary data submitted to US Food and Drug Administration. BMJ 2009; 339: b2880.
[http://dx.doi.org/10.1136/bmj.b2880] [PMID: 19671933]
[59]
Le Noury J, Nardo JM, Healy D, et al. Restoring Study 329: efficacy and harms of paroxetine and imipramine in treatment of major depression in adolescence. BMJ 2015; 351: h4320.
[http://dx.doi.org/10.1136/bmj.h4320] [PMID: 26376805]
[60]
Roth D, Boyle E, Beer D, Malik A, deBruyn J. Depressing research. Lancet 2004; 363(9426): 2087.
[http://dx.doi.org/10.1016/S0140-6736(04)16462-3] [PMID: 15207963]
[61]
Gibbons RD, Brown CH, Hur K, et al. Early evidence on the effects of regulators’ suicidality warnings on SSRI prescriptions and suicide in children and adolescents. Am J Psychiatry 2007; 164(9): 1356-63.
[http://dx.doi.org/10.1176/appi.ajp.2007.07030454] [PMID: 17728420]
[62]
Spielmans GI, Spence-Sing T, Parry P. Duty to warn: Antidepressant black box suicidality warning is empirically justified. Front Psychiatry 2020.
[63]
Ignaszewski MJ, Waslick B. Update on randomized placebo-controlled trials in the past decade for treatment of major depressive disorder in child and adolescent patients: A systematic review. J Child Adolesc Psychopharmacol 2018; 28(10): 668-75.
[http://dx.doi.org/10.1089/cap.2017.0174] [PMID: 30063169]
[64]
Vitiello B, Silva SG, Rohde P, et al. Suicidal events in the treatment for adolescents with depression study (TADS). J Clin Psychiatry 2009; 70(5): 741-7. a
[http://dx.doi.org/10.4088/JCP.08m04607] [PMID: 19552869]
[65]
March JS, Silva S, Petrycki S, et al. The treatment for adolescents with depression study (TADS): long-term effectiveness and safety outcomes. Arch Gen Psychiatry 2007; 64(10): 1132-43.
[http://dx.doi.org/10.1001/archpsyc.64.10.1132] [PMID: 17909125]
[66]
Brent DA, Greenhill LL, Compton S, et al. The Treatment of Adolescent Suicide Attempters study (TASA): Predictors of suicidal events in an open treatment trial. J Am Acad Child Adolesc Psychiatry 2009; 48(10): 987-96.
[http://dx.doi.org/10.1097/CHI.0b013e3181b5dbe4] [PMID: 19730274]
[67]
Vitiello B, Brent DA, Greenhill LL, et al. Depressive symptoms and clinical status during the Treatment of Adolescent Suicide Attempters (TASA) Study. J Am Acad Child Adolesc Psychiatry 2009; 48(10): 997-1004. b
[http://dx.doi.org/10.1097/CHI.0b013e3181b5db66] [PMID: 20854770]
[68]
Cipriani A, Hawton K, Stockton S, Geddes JR. Lithium in the prevention of suicide in mood disorders: Updated systematic review and meta-analysis. BMJ 2013; 346: f3646.
[http://dx.doi.org/10.1136/bmj.f3646] [PMID: 23814104]
[69]
National Institute of Health and Care Excellence. Depression in children and young people: diagnosis and management NICE Guidelines 134 2019. Available from: httss://nice.org,uk/guidance/ng134
[70]
Whiting D, Fazel S. How accurate are suicide risk prediction models? Asking the right questions for clinical practice. Evid Based Ment Health 2019; 22(3): 125-8.
[http://dx.doi.org/10.1136/ebmental-2019-300102] [PMID: 31248976]
[71]
Strawn JR, Welge JA, Wehry AM, Keeshin B, Rynn MA. Efficacy and tolerability of antidepressants in pediatric anxiety disorders: A systematic review and meta-analysis. Depress Anxiety 2015; 32(3): 149-57.
[http://dx.doi.org/10.1002/da.22329] [PMID: 25449861]
[72]
Luft MJ, Lamy M, DelBello MP, McNamara RK, Strawn JR. Antidepressant-induced activation in children and adolescents: Risk, recognition and management. Curr Probl Pediatr Adolesc Health Care 2018; 48(2): 50-62.
[http://dx.doi.org/10.1016/j.cppeds.2017.12.001] [PMID: 29358037]
[73]
Revet A, Montastruc F, Roussin A, Raynaud JP, Lapeyre-Mestre M, Nguyen TTH. Antidepressants and movement disorders: A postmarketing study in the world pharmacovigilance database. BMC Psychiatry 2020; 20(1): 308.
[http://dx.doi.org/10.1186/s12888-020-02711-z] [PMID: 32546134]
[74]
Simon GE, Perlis RH. Personalized medicine for depression: can we match patients with treatments? Am J Psychiatry 2010; 167(12): 1445-55.
[http://dx.doi.org/10.1176/appi.ajp.2010.09111680] [PMID: 20843873]
[75]
Hazell P, O’Connell D, Heathcote D, Henry D. Tricyclic drugs for depression in children and adolescents. Cochrane Database Syst Rev 2002; (2): CD002317
[PMID: 12076448]
[76]
Solhkhah R, Wilens TE, Daly J, Prince JB, Van Patten SL, Biederman J. Bupropion SR for the treatment of substance-abusing outpatient adolescents with attention-deficit/hyperactivity disorder and mood disorders. J Child Adolesc Psychopharmacol 2005; 15(5): 777-86.
[http://dx.doi.org/10.1089/cap.2005.15.777] [PMID: 16262594]
[77]
Findling RL, Robb AS, DelBello MP, et al. A 6-month open-label extension study of vortioxetine in pediatric patients with depressive or anxiety disorders. J Child Adolesc Psychopharmacol 2018; 28(1): 47-54.
[http://dx.doi.org/10.1089/cap.2017.0047] [PMID: 29035574]
[78]
Haapasalo-Pesu KM, Vuola T, Lahelma L, Marttunen M. Mirtazapine in the treatment of adolescents with major depression: an open-label, multicenter pilot study. J Child Adolesc Psychopharmacol 2004; 14(2): 175-84.
[http://dx.doi.org/10.1089/1044546041649110] [PMID: 15319015]
[79]
Boafo A, Greenham S, Sullivan M, et al. Medications for sleep disturbance in children and adolescents with depression: a survey of Canadian child and adolescent psychiatrists. Child Adolesc Psychiatry Ment Health 2020; 14: 10.
[http://dx.doi.org/10.1186/s13034-020-00316-8] [PMID: 32175006]
[80]
Di Vincenzo JD, Siegel A, Lipsitz O, et al. The effectiveness, safety and tolerability of ketamine for depression in adolescents and older adults: A systematic review. J Psychiatr Res 2021; 137: 232-41.
[http://dx.doi.org/10.1016/j.jpsychires.2021.02.058] [PMID: 33706168]
[81]
Cervesi C, Park SY, Galling B, et al. Extent, time course, and moderators of antipsychotic treatment in youth with mood disorders: Results of a Meta-Analysis and Meta-Regression analyses. J Clin Psychiatry 2017; 78(3): 347-57.
[http://dx.doi.org/10.4088/JCP.15r10435] [PMID: 28068462]
[82]
Detke HC, DelBello MP, Landry J, Usher RW. Olanzapine/Fluoxetine combination in children and adolescents with bipolar I depression: a randomized, double-blind, placebo-controlled trial. J Am Acad Child Adolesc Psychiatry 2015; 54(3): 217-24.
[http://dx.doi.org/10.1016/j.jaac.2014.12.012] [PMID: 25721187]
[83]
DelBello MP, Goldman R, Phillips D, Deng L, Cucchiaro J, Loebel A. Efficacy and safety of lurasidone in children and adolescents with Bipolar I Depression: A double-blind, placebo-controlled study. J Am Acad Child Adolesc Psychiatry 2017; 56(12): 1015-25.
[http://dx.doi.org/10.1016/j.jaac.2017.10.006] [PMID: 29173735]
[84]
Hafeman DM, Rooks B, Merranko J, et al. Lithium versus other mood-stabilizing medications in a longitudinal study of youth diagnosed with Bipolar Disorder. J Am Acad Child Adolesc Psychiatry 2020; 59(10): 1146-55.
[http://dx.doi.org/10.1016/j.jaac.2019.06.013] [PMID: 31369795]
[85]
Safer DJ, Zito JM. Treatment-emergent adverse events from selective serotonin reuptake inhibitors by age group: children versus adolescents. J Child Adolesc Psychopharmacol 2006; 16(1-2): 159-69.
[http://dx.doi.org/10.1089/cap.2006.16.159] [PMID: 16553536]
[86]
Padala PR, Padala KP, Majagi AS, Garner KK, Dennis RA, Sullivan DH. Selective serotonin reuptake inhibitors-associated apathy syndrome: A cross sectional study. Medicine (Baltimore) 2020; 99(33)e21497
[http://dx.doi.org/10.1097/MD.0000000000021497] [PMID: 32871995]
[87]
Jerrell JM. Neuroendocrine-related adverse events associated with antidepressant treatment in children and adolescents. CNS Neurosci Ther 2010; 16(2): 83-90.
[http://dx.doi.org/10.1111/j.1755-5949.2009.00106.x] [PMID: 19769598]
[88]
Caye A, Pilz LK, Maia AL, Hidalgo MP, Furukawa TA, Kieling C. The impact of selective serotonin reuptake inhibitors on the thyroid function among patients with major depressive disorder: A systematic review and meta-analysis. Eur Neuropsychopharmacol 2020; 33: 139-45.
[http://dx.doi.org/10.1016/j.euroneuro.2020.01.011] [PMID: 32046933]
[89]
Feuer AJ, Demmer RT, Thai A, Vogiatzi MG. Use of selective serotonin reuptake inhibitors and bone mass in adolescents: An NHANES study. Bone 2015; 78: 28-33.
[http://dx.doi.org/10.1016/j.bone.2015.04.042] [PMID: 25940460]

Rights & Permissions Print Cite
Article Metrics
22
1
© 2024 Bentham Science Publishers | Privacy Policy